Arcutis Biotherapeutics Stock Alpha and Beta Analysis
| ARQT Stock | USD 26.30 0.10 0.38% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Arcutis Biotherapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Arcutis Biotherapeutics over a specified time horizon. Remember, high Arcutis Biotherapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Arcutis Biotherapeutics' market risk premium analysis include:
Beta 0.47 | Alpha 0.39 | Risk 2.96 | Sharpe Ratio 0.0414 | Expected Return 0.12 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Arcutis Biotherapeutics Backtesting, Arcutis Biotherapeutics Valuation, Arcutis Biotherapeutics Correlation, Arcutis Biotherapeutics Hype Analysis, Arcutis Biotherapeutics Volatility, Arcutis Biotherapeutics History and analyze Arcutis Biotherapeutics Performance. Arcutis Biotherapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Arcutis Biotherapeutics market risk premium is the additional return an investor will receive from holding Arcutis Biotherapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arcutis Biotherapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Arcutis Biotherapeutics' performance over market.| α | 0.39 | β | 0.47 |
Arcutis Biotherapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Arcutis Biotherapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Arcutis Biotherapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Arcutis Biotherapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Arcutis Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Arcutis Biotherapeutics shares will generate the highest return on investment. By understating and applying Arcutis Biotherapeutics stock market price indicators, traders can identify Arcutis Biotherapeutics position entry and exit signals to maximize returns.
Arcutis Biotherapeutics Return and Market Media
The median price of Arcutis Biotherapeutics for the period between Tue, Oct 28, 2025 and Mon, Jan 26, 2026 is 27.89 with a coefficient of variation of 11.5. The daily time series for the period is distributed with a sample standard deviation of 3.11, arithmetic mean of 27.03, and mean deviation of 2.55. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Arcutis Biotherapeutics Valuation Snapshot Following FDA Acceptance for ZORYVE Pediatric Use Expansion | 11/18/2025 |
2 | Disposition of 1561 shares by Matsuda Masaru of Arcutis Biotherapeutics at 28.5 subject to Rule 16b-3 | 11/19/2025 |
3 | Disposition of 48945 shares by Watanabe Todd of Arcutis Biotherapeutics at 30.3556 subject to Rule 16b-3 | 11/24/2025 |
4 | Disposition of 10000 shares by Welgus Howard G. of Arcutis Biotherapeutics at 30.2133 subject to Rule 16b-3 | 12/01/2025 |
5 | Arcutis Biotherapeutics, Inc. ARQT Shares Sold by XTX Topco Ltd | 12/05/2025 |
6 | Disposition of 11500 shares by Burnett Patrick of Arcutis Biotherapeutics at 28.9436 subject to Rule 16b-3 | 12/15/2025 |
7 | 5 Biotech Stocks to Watch for Potential Upside | 12/17/2025 |
8 | Arcutis Stock Is Up 100 percent in a Year but Heres Why One Fund Still Sold 1 Million Shares | 12/23/2025 |
9 | Arcutis Biotherapeutics Cut to Buy at Wall Street Zen | 12/30/2025 |
10 | Arcutis Biotherapeutics Stock Price Up 3.4 percent Time to Buy | 12/31/2025 |
11 | Disposition of 2490 shares by Burnett Patrick of Arcutis Biotherapeutics at 28.9822 subject to Rule 16b-3 | 01/05/2026 |
12 | A Look At Arcutis Biotherapeutics Valuation After ZORYVE Driven Revenue Growth And Ongoing Losses | 01/09/2026 |
13 | Arcutis Biotherapeutics Shares Unloaded Rep. Gilbert Ray Cisneros, Jr. - MarketBeat | 01/14/2026 |
14 | Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference | 01/22/2026 |
About Arcutis Biotherapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Arcutis or other stocks. Alpha measures the amount that position in Arcutis Biotherapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 0.42 | 1.35 | 1.21 | 1.27 | Days Of Inventory On Hand | 961.28 | 277.18 | 318.76 | 302.82 |
Arcutis Biotherapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Arcutis Biotherapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcutis Biotherapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Arcutis Biotherapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Arcutis Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Arcutis Biotherapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Arcutis Biotherapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.